QNCX Stock Forecast & Price Target

Quince Therapeutics Inc. is navigating the preclinical stage with a robust pipeline that includes advanced therapies for challenging conditions such as Ataxia-Telangiectasia and Duchenne Muscular Dystrophy, attracting attention due to the company's strong safety record and favorable toxicity profile reinforced by prior clinical trials. The impressive patient retention, evidenced by all participants opting for open label extensions and low discontinuation rates, reflects a high level of interest and confidence in their therapies, which addresses significant unmet medical needs. The anticipated operational milestone from the pivotal Phase 3 NEAT clinical trial and the ability to scale solutions for broader patient demographics further solidify a positive outlook on the company's future prospects.

Quince Therapeutics Inc reported a net loss of $13.3 million for Q3 2025, indicating significant financial challenges typically associated with early-stage biotechnology companies. As of September 30, 2025, the company held cash and short-term investments totaling $26.3 million, which may limit its ability to sustain ongoing research and development initiatives. The breakdown of expenses showed that R&D accounted for $8.1 million and G&A for $3.3 million, underscoring the high costs associated with advancing its drug pipeline while still lacking revenue generation.